Rubraca

Active Ingredient(s): Rucaparib
FDA Approved: * December 19, 2016
Pharm Company: * Clovis Oncology, Inc.
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Rubraca Overview

Rucaparib (brand name Rubraca roo-BRAH-ka, code name AG 014699) is a PARP inhibitor being investigated as a potential anti-cancer agent. Rucaparib is the first-in-class clinical candidate targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1), and was first synthesised as part of a collaboration between scientists working in Northern Institute of Cancer Research and Medical School of Newcastle University, alongside Agouron Pharmaceuticals (San Diego).[2] It is being developed b...

Read more Rubraca Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Rucaparib

Recent Rubraca Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Rucaparib
  • Tablet: 200mg, 300mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Rubraca: (2 results)

Sorted by National Drug Code
  • 69660-201 Rubraca 200 mg Oral Tablet, Film Coated by Clovis Oncology, Inc.
  • 69660-203 Rubraca 300 mg Oral Tablet, Film Coated by Clovis Oncology, Inc.

Other drugs which contain Rucaparib or a similar ingredient: (1 result)